Drug news
Lorqess is filed at EU by Arena Pharma for weight loss
Arena Pharma has filed at the EU its selective serotonin 2C receptor agonist, Lorqess (lorcaserin)for use in weight loss and maintenance of weight loss in patients who are obese (BMI>30) or who are overweight (BMI>27) and have at least one weight-related comorbid condition. The rights in the USA are held by Eisai and outside the EU the rights are held by Arena Pharma.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.